Retina Implant expands EU retinitis trials

Retina Implant’s expansion of European clinical trials was an early-stage clinical and regulatory step for one of the better-known “bionic eye” programs aimed at retinitis pigmentosa, a degenerative inherited retinal disease. Ophthalmology Times reported that the company’s scientific advisory board approved a broader multicentre phase after the study began in Tübingen, Germany, in 2010. The device was designed to sit under the retina and convert light into electrical signals that could stimulate surviving retinal circuitry. The trial mattered because it moved the program beyond single-site testing and into a format closer to how device developers generate broader clinical evidence. ### What exactly was approved in Europe? Ophthalmology Times reported that Retina Implant’s scientific advisory board approved the expansion of European clinical trials for its subretinal implant in patients with retinitis pigmentosa. The report said the multicentre phase of the company’s second human clinical trial would take place in Germany, Budapest, London and Oxford. (ophthalmologytimes.com) The 2010 trial design also differed from shorter feasibility studies because patients were to keep the implant permanently so it could be used in everyday situations, according to the report. That made the study a test not only of surgical placement and device function, but also of how the implant performed outside controlled lab sessions. (ophthalmologytimes.com) ### How does a subretinal implant try to restore vision? The Alpha-series approach developed by Retina Implant AG uses a subretinal microelectronic chip placed beneath the retina, in the location where damaged photoreceptors would normally convert light into neural signals. EyeWiki describes the company’s platform as a subretinal micro-photodiode array retinal prosthesis developed in Germany, with Alpha-IMS later approved in Europe and then succeeded by Alpha-AMS. (ophthalmologytimes.com) The American Academy of Ophthalmology said retinal prostheses for retinitis pigmentosa are intended for patients whose photoreceptors are severely damaged while downstream retinal neurons remain relatively spared. In practical terms, the implant does not restore normal sight; it attempts to provide limited visual perception by electrically stimulating remaining retinal pathways. ### Why were cities like London and Oxford part of the next phase? (eyewiki.org) The multicentre phase listed by Ophthalmology Times — Germany, Budapest, London and Oxford — showed the company was moving to broader European enrollment rather than relying on one surgical team in Tübingen. Multi-site testing can help device developers compare outcomes across surgeons, hospitals and patient populations, though the report did not provide a target enrollment number. (aao.org) European expansion also reflected the way retinal prosthesis programs were being developed at the time: through specialist ophthalmology centers with experience in inherited retinal disease, vitreoretinal surgery and rehabilitation. The locations named in the report were all major academic or clinical hubs capable of handling complex implantation and follow-up. That point is an inference based on the named trial sites and the specialized nature of retinal prosthesis care. (ophthalmologytimes.com) ### Where does this fit in the broader retinitis pigmentosa field? Retinitis pigmentosa affects roughly one in 3,500 people in the United States and Europe, according to the American Academy of Ophthalmology. The condition progressively destroys photoreceptors and can leave patients with severe vision loss or near-total blindness. More recent work in the field has expanded beyond implants to include gene therapy and optogenetics. (ophthalmologytimes.com) ARVO reported first-in-human gene therapy data for advanced retinitis pigmentosa in 2026, while Ophthalmology Times separately reported an FDA regenerative medicine designation for an optogenetic therapy candidate earlier this year. Those newer programs underscore how retinal implants now sit alongside several technology platforms rather than standing alone. (aao.org) ### What would the next milestone have been after this approval? The immediate next milestone after the advisory-board decision was the multicentre clinical phase in Germany, Budapest, London and Oxford, as described by Ophthalmology Times. The report said the study had already commenced in Tübingen in 2010, making the expansion a step toward collecting broader human data on permanent use of the implant in daily life. (arvo.org) Later generations of Retina Implant devices, including Alpha-AMS, appeared in subsequent clinical literature and trial records, showing the program continued to evolve after the early European expansion described here. EyeWiki and later trial databases indicate that follow-on versions were studied in later years, though those developments were separate from the original 2010 multicentre decision. (eyewiki.org) (ophthalmologytimes.com)